We're developing the first longevity drugs for dogs.

Our approach

Aging is the most significant modifiable risk factor for many degenerative and chronic diseases in adult dogs. Targeting the ways dogs age and decline over time may be one of the most effective and practical ways to increase their healthy lifespan.

At Loyal, our approach is to help dogs live longer and stay healthier as they age by developing drugs that target the underlying processes that lead to age-associated disease and disability.

Key Statistics

• 3 drug programs in development
• 70 veterinary practices in STAY clinical trial
• 1,317 dogs enrolled in STAY clinical trial

Senior dogs

LOY-002 intends to preserve senior dogs’ quality of life and extend their lifespan by improving insulin sensitivity and lowering insulin levels. By addressing a root cause of aging, LOY-002 aims to give senior dogs more good years.

Target population

Dogs age 10+, 14+ lb

How it works

Improving metabolic health and improving insulin sensitivity through a once-daily pill

FDA approval progress

2/3 major requirements completed. FDA approval not guaranteed.

RXE: preliminary efficacy data

Accepted

TAS: safety studies

Accepted

CMC: manufacturing

In progress

Good news for senior dogs

We've hit a major milestone. LOY-002 just completed the second of three major requirements for FDA conditional approval. It's the clearest signal yet that a longevity drug for dogs could be available soon.

The Loyal Learning Hub

The Loyal Learning Hub is the definitive resource for canine aging. Our free library of RACE-approved courses helps veterinary teams easily earn CE and deliver better care to senior dogs.